SCHEMBL290323

SCHEMBL290323

O=C(c1ccccc1)c1coc2c(Br)c(Br)c(O)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.56
KMT2A Q03164 7/20 0.48
MEN1 O00255 6/20 0.48
MAPT P10636 6/20 0.48
ALDH1A1 P00352 4/20 0.48
RAB9A P51151 3/20 0.48
CREBBP Q92793 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 3/20 0.44
HPGD P15428 3/20 0.44
MAPK1 P28482 3/20 0.44
PKM P14618 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CASP3 P42574 2/20 0.44
SENP8 Q96LD8 2/20 0.44
SENP7 Q9BQF6 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL290225 0.90 PTGS2 (0.52) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL290295 0.86 PTGS2 (0.51) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL289809 0.86 PTGS2 (0.68) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL290558 0.85 RAB9A (0.45) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL289532 0.83 NPC1 (0.57) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL289028 0.82 SRD5A2 (0.44) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL290149 0.82 PTGS2 (0.44) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL290499 0.82 PTGS2 (0.47) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL290191 0.81 KMT2A (0.54) PTGS2KMT2AMEN1MAPTRAB9A
SCHEMBL290073 0.81 PTGS2 (0.52) PTGS2KMT2AMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2959898-A1 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2015-12-30 EP disclosed
EP-2427057-B1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN KETTERING INST CANCER (US) 2015-08-12 EP disclosed
US-8614237-B2 Benzofuran-4,5-diones as selective peptide deformylase inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-12-24 US disclosed
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-03-22 US disclosed
EP-2427057-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2012-03-14 EP disclosed
WO-2010129049-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS PDF, EIF5B, EIF4E PTGS2 2098/4885KMT2A 3066/4885MEN1 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.